BioSpace News Archive

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated results from a Phase I/IIa study of its lead product candidate, OpRegen®,

Imprivata®, the digital identity company for healthcare, today announced that it was named to the Constellation ShortList™ for Healthcare Medical Device Security in Q1 2020.

Ally Bridge Group, a leading global life science investment group, has announced that it recently led US$70 million investments in two Israeli life science companies over the last 2 months.

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today reported meaningful progress in the development of its pharmaceutical grade version of Tauri-Gum™.

Current Health, which offers the leading FDA-cleared, artificial intelligence (AI)-powered remote patient management platform, today announced it has appointed healthcare industry veteran Todd Rothenhaus to its Board of Directors.

Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference in New York City on Wednesday, February 26, 2020 at 2:00 p.m. EST.

Turning Point Therapeutics, Inc. announced that President and CEO Athena Countouriotis, M.D., will participate in the 9th Annual SVB Leerink Global Healthcare Conference on Feb. 27 in New York and the Cowen 40th Annual Healthcare Conference on March 2 in Boston..

NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- AXIM ® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM ® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that it has completed the first phase of its pharmacokinetic clinical study on its cannabinoid-based chewing gum with dronabinol, a synthetic form of tetrahydrocannabinol (THC). The multi-phase study is aimed to understand how cannabis may serve as a

Livongo Health, Inc., (Nasdaq: LVGO), the leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced that executives from the Company will be presenting at the following upcoming investor conferences:

Sojournix, a clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative new medicines for the treatment of women’s health and neuroendocrine disorders, announces that Daniel Grau, Chief Executive Officer of Sojournix, will present at the Cowen and Company 40th Annual Health Care Conference on Wednesday, March 4